Agios Pharmaceuticals (NASDAQ:AGIO) Issues Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.15, FiscalAI reports. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The company had revenue of $55.39 million during the quarter, compared to analysts’ expectations of $51.65 million.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Agios reported record third-quarter revenue of $55.4 million, more than four times the year-ago quarter, with $48.7 million from U.S. sales. The company attributed growth to AQVESME’s thalassemia launch and said U.S. revenue rose 20% sequentially.
• The FDA’s request for additional information on whether a REMS is needed for mitapivat in sickle cell disease extended the review by three months, moving the PDUFA goal date to February 1, 2027. Agios said it is discussing labeling and potential REMS elements with the agency and remains launch-ready.
• AQVESME had 619 completed start forms since launch—about 15% of Agios’s roughly 4,000-patient target population—with another 48 in process. The company reported approximately 75% of patients remained on therapy at six months and said demand is broadening to community practices and non-transfusion-dependent patients.
• Agios highlighted upcoming sickle cell data on sustained hemoglobin responses and post-hoc kidney and cardiac measures, while noting the organ findings are exploratory. It also expects to present AG-236 healthy-volunteer data at ASH, including effects lasting through six months, and plans to begin its PV phase II/III program by year-end.
• Agios ended the quarter with $907 million in cash and expects 2026 operating expenses to remain approximately flat year over year, excluding specified one-time items. It plans to reduce R&D headcount by more than 35% during 2026, with savings expected in 2027, and is targeting non-GAAP profitability in 2028.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock traded down $3.11 during midday trading on Thursday, hitting $28.27. 2,551,343 shares of the company were exchanged, compared to its average volume of 1,280,898. The firm has a market capitalization of $1.69 billion, a PE ratio of -4.03 and a beta of 0.66. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The business has a fifty day simple moving average of $33.37 and a two-hundred day simple moving average of $31.75.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios reported a third-quarter loss of $1.09 per share, better than analyst expectations, while revenue of $55.39 million exceeded the $51.65 million estimate. Mitapivat revenue also rose more than fourfold, signaling commercial growth. Agios Reports Third Quarter 2026 Financial Results and Provides Business Update Agios Q3 Mitapivat Revenue Surges More Than Fourfold
• Neutral Sentiment: The FDA is expected to decide on mitapivat for sickle cell disease in February 2027, setting a significant future catalyst but leaving investors waiting for a regulatory outcome. Agios also plans to present new mitapivat and AG-236 data at ASH 2026. FDA Decision Timing Agios ASH 2026 Clinical Data
• Negative Sentiment: Agios plans to eliminate more than 100 R&D roles. The cuts could reduce costs, but may also raise concerns about research capacity as the company works toward a sickle-cell approval. The company remains loss-making, which may temper the impact of its quarterly beat. Agios R&D Role Cuts

Analyst Upgrades and Downgrades

Several brokerages recently commented on AGIO. TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. JPMorgan Chase & Co. lifted their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Truist Financial decreased their target price on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Bank of America increased their price target on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.50.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the sale, the insider owned 54,645 shares in the company, valued at approximately $2,059,570.05. This represents a 12.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,855 shares of company stock valued at $371,112 over the last three months. Insiders own 5.40% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.